Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2552 - Prognostic value of microsatellite instability status in stage II/III rectal cancer patients who received upfront surgery


09 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


Chung Ryul Oh


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


C.R. Oh1, J.E. Kim2, Y.S. Hong2, S.Y. Kim2, T.W. Kim2

Author affiliations

  • 1 Department Of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR


Abstract 2552


Microsatellite instability (MSI) is one of the most important prognostic factors in patients with colon cancer but the impact of MSI in rectal cancer, which is known to have a lower incidence of MSI-high (MSI-H) tumours than proximal colon cancer, has not been fully evaluated. We studied whether MSI status affects survival in stage II and III rectal cancer patients who underwent upfront curative resection.


1138 patients who had operation between February 2008 and August 2015 in a single, tertiary care center in South Korea were included and PCR-based MSI testing was performed on tumour tissue from each patient. Study endpoints were disease free survival (DFS) and overall survival (OS).


Among 1138 patients, 25 (2.2%) had MSI-H tumours. Compared with microsatellite stable (MSS) or MSI-low (MSI-L) tumours, MSI-H showed similar clinical characteristics including age at diagnosis, gender, tumour location and pathologic tumour stage but they were highly associated with histological grade of tumour (p = 0.005) and presence of family history of colorectal cancers (p = 0.003). The 5-year DFS rates for patients with MSI-H and MSS/MSI-L were 78.0% and 69.2%, respectively (p = 0.637), and the 5-year OS rate was 84.0% with MSI-H and 82.4% with MSS/MSI-L (p = 0.735). On multivariate Cox regression analysis, there was also no significant difference in either DFS (p = 0.855) or OS (p = 0.912) for the patients with rectal cancer based on MSI status.


Our results suggested that MSI has no definite prognostic role in patients with rectal cancer. MSI status was associated with differentiation of tumour and family history of colorectal cancer.

Clinical trial identification

Legal entity responsible for the study

Department of Oncology, Asan Medical Center, Seoul, Republic of Korea




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.